Cargando…

Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia

With the demonstration of improved survival of some acute myeloid leukemia (AML) patients with the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO), CD33 has been validated as a target for antigen-specific immunotherapy. Since previous studies identified a CD33 splice variant missing exon 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laszlo, George S., Harrington, Kimberly H., Gudgeon, Chelsea J., Beddoe, Mary E., Fitzgibbon, Matthew P., Ries, Rhonda E., Lamba, Jatinder K., McIntosh, Martin W., Meshinchi, Soheil, Walter, Roland B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190023/ https://www.ncbi.nlm.nih.gov/pubmed/27248327 http://dx.doi.org/10.18632/oncotarget.9674

Ejemplares similares

Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin
por: Lamba, Jatinder K., et al.
Publicado: (2021)

High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
por: Laszlo, George S., et al.
Publicado: (2015)

Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
por: Laszlo, George S., et al.
Publicado: (2016)

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
por: Stockard, Bradley, et al.
Publicado: (2018)

SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia
por: Marrero, Richard J., et al.
Publicado: (2023)

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk
por: Harrington, Kimberly H., et al.
Publicado: (2015)

Inflammatory bone marrow signaling in pediatric acute myeloid leukemia distinguishes patients with poor outcomes
por: Bolouri, Hamid, et al.
Publicado: (2022)

T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330
por: Laszlo, G S, et al.
Publicado: (2015)

Proteomics: a new era in pediatric acute myeloid leukemia research
por: Lamba, Jatinder K., et al.
Publicado: (2022)

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia
por: McNeer, Nicole A., et al.
Publicado: (2019)

“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
por: Knight, Tristan E., et al.
Publicado: (2022)

Current Landscape of Genome-Wide Association Studies in Acute Myeloid Leukemia: A Review
por: Marrero, Richard J., et al.
Publicado: (2023)

ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 Trial
por: Rafiee, Roya, et al.
Publicado: (2019)

Targeting CD33 for acute myeloid leukemia therapy
por: Liu, Jingjing, et al.
Publicado: (2022)

Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling
por: Tarlock, Katherine, et al.
Publicado: (2018)

The clinical and biological characteristics of NUP98-KDM5A pediatric acute myeloid leukemia
por: Noort, Sanne, et al.
Publicado: (2020)

Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia
por: Farrar, Jason E., et al.
Publicado: (2023)

Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia
por: Mamolo, Carla, et al.
Publicado: (2020)

Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
por: Le, Quy, et al.
Publicado: (2021)

MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia
por: Lim, Emilia L., et al.
Publicado: (2017)

Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia
por: Braun, Theodore P., et al.
Publicado: (2019)

Functional Dependency Analysis Identifies Potential Druggable Targets in Acute Myeloid Leukemia
por: Zhou, Yujia, et al.
Publicado: (2020)

MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia
por: Bhise, Neha S., et al.
Publicado: (2019)

Development of siRNA-Loaded Lipid Nanoparticles Targeting Long Non-Coding RNA LINC01257 as a Novel and Safe Therapeutic Approach for t(8;21) Pediatric Acute Myeloid Leukemia
por: Connerty, Patrick, et al.
Publicado: (2021)

Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children’s Oncology Group study
por: Hoff, Fieke W., et al.
Publicado: (2022)

Author Correction: Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia
por: Braun, Theodore P., et al.
Publicado: (2022)

CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes
por: Huang, Benjamin J., et al.
Publicado: (2021)

Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33
por: Romão, Ema, et al.
Publicado: (2020)

MicroRNA-150 Expression Induces Myeloid Differentiation of Human Acute Leukemia Cells and Normal Hematopoietic Progenitors
por: Morris, Valerie A., et al.
Publicado: (2013)

Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group
por: Nagarajan, Rajaram, et al.
Publicado: (2019)

Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia
por: Huang, Benjamin J., et al.
Publicado: (2022)

In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33(+) Acute Myeloid Leukemia
por: Dutour, A., et al.
Publicado: (2012)

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
por: Ehninger, A, et al.
Publicado: (2014)

Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia
por: Albinger, Nawid, et al.
Publicado: (2022)

Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia
por: Lamba, Jatinder K., et al.
Publicado: (2018)

AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin
por: Rosen, David B., et al.
Publicado: (2013)

CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin
por: Molica, Matteo, et al.
Publicado: (2021)

Correction: Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia
por: Lamba, Jatinder K., et al.
Publicado: (2018)

Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia
por: Bertrums, Eline J. M., et al.
Publicado: (2023)

Pseudohyperkalemia in chronic lymphocytic leukemia
por: Gudgeon, Patrick, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mk6l0mb25r5cc06cmonpjccr8q